13.09.2010 • News • Novo Nordisk • Insulin

Novo Nordisk Says to Double China Research and Development Centre

Denmark's Novo Nordisk , the world's biggest maker of insulin, said on Monday it would double the size of its research and development centre in Beijing to 200 employees by 2015.
"The expansion will mainly be dedicated to a new diabetes research unit," Novo Nordisk said in a statement. The company did not give any financial details

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Top-Feature